Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXTEND: Eltrombopag in ITP
NCT00351468Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2006
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 31
01
Overview
Phase 3, open-label, single-arm trial of eltrombopag in immune thrombocytopenia (ITP), sponsored by Novartis. Primary endpoint: Overall Summary of On-Therapy Adverse Events up to 8 years. Started Jun 2006; status: completed.
02
Drugs
eltrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT00351468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00351468.